Int. J. Dev. Biol. 55: 395 - 398 (2011)

https://doi.org/10.1387/ijdb.103217fb

Vol 55, Issue 4-5

Special Issue: Angiogenesis in Development & Cancer

Anti-angiogenesis in cancer; met and unmet goals - an interview with Robert Kerbel

Review | Published: 19 July 2011

Francesco Bertolini*

Laboratory of Hematology-Oncology, European Institute of Oncology, Milan, Italy

Abstract

Robert Kerbel is one of the most influential scientists in the field of cancer-related angiogenesis and anti-angiogenic therapies. Along with the late Judah Folkman, Dr. Kerbel has also pioneered the use of continuous low dose chemotherapy for cancer treatment, an approach which is now widely used for many types of cancer and is a promising backbone to be associated with novel targeted therapies. In this interview, Dr. Kerbel describes the steps that moved his career towards the angiogenesis field, the already achieved biological and clinical results and the unmet goals.

Keywords

Vasculogenesis, metronomic chemotherapy, VEGF, anti-VEGF, TKI